



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BR642 : Breast invasive lobular carcinoma tissue array, including TNM, clinical stage and pathology grade, 64 cases/ 64 cores

Microarray Panel	Breast invasive lobular carcinoma tissue microarray, containing 64 cases of invasive lobular carcinoma, single core per case		
Cores	64		
Cases	64		
Row number	8		
Column number	8		
Core Diameter (mm)	1.5		
Thickness (µm)	5		
Tissue Array Type	FFPE		
Species	Human		
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.		
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, "" means invalid core; "-" means no applicable or negative in IHC markers.		

	1	2	3	4	5	6	7	8
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
D	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
E	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
F	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
G	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
H	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre

Legend:Bre - Breast

● - Malignant tumor, ● - Malignant tumor (stage I), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB)

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	44	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant	
A2	2	47	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant	
A3	3	49	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
A4	4	46	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
A5	5	34	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
A6	6	37	F	Breast	Invasive lobular carcinoma (cataplasia)	T2N0M0		IIA	malignant	
A7	7	68	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
A8	8	37	F	Breast	Invasive lobular carcinoma	T4N1M0		IIIB	malignant	
B1	9	74	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
B2	10	53	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
B3	11	48	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
B4	12	42	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant	
B5	13	52	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
B6	14	49	F	Breast	Invasive lobular carcinoma	T3N2M0		IIIA	malignant	
B7	15	53	F	Breast	Invasive lobular carcinoma	T4N1M0		IIIB	malignant	
B8	16	50	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C1	17	47	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C2	18	41	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
C3	19	69	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C4	20	66	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C5	21	59	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C6	22	41	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
C7	23	35	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
C8	24	51	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	

D1	25	47	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
D2	26	73	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
D3	27	61	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
D4	28	35	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant	
D5	29	53	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
D6	30	58	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
D7	31	47	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
D8	32	49	F	Breast	Invasive lobular carcinoma	T3N1M0		IIIA	malignant	
E1	33	48	F	Breast	Invasive lobular carcinoma	T2N2M0		IIIA	malignant	
E2	34	40	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
E3	35	52	F	Breast	Invasive lobular carcinoma	T4N0M0		IIIB	malignant	
E4	36	43	F	Breast	Invasive lobular carcinoma (sparse)	T2N0M0		IIA	malignant	
E5	37	50	F	Breast	Invasive lobular carcinoma	T3N2M0		IIIA	malignant	
E6	38	42	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
E7	39	57	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
E8	40	46	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
F1	41	50	F	Breast	Invasive lobular carcinoma	T2N2M0		IIIA	malignant	
F2	42	60	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
F3	43	63	F	Breast	Invasive lobular carcinoma	T3N0M0		IIB	malignant	
F4	44	58	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
F5	45	51	M	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
F6	46	72	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
F7	47	31	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
F8	48	49	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
G1	49	45	F	Breast	Invasive lobular carcinoma (breast tissue)	T2N1M0		IIB	malignant	
G2	50	55	F	Breast	Invasive lobular carcinoma (sparse)	T2N2M0		IIIA	malignant	
G3	51	45	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
G4	52	64	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
G5	53	54	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
G6	54	55	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
G7	55	59	F	Breast	Invasive lobular carcinoma (tumoral necrosis)	T2N0M0		IIA	malignant	
G8	56	50	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
H1	57	47	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
H2	58	58	F	Breast	Invasive lobular carcinoma	T1N0M0		I	malignant	
H3	59	46	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
H4	60	56	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
H5	61	49	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
H6	62	44	F	Breast	Invasive lobular carcinoma	T2N0M0		IIA	malignant	
H7	63	48	F	Breast	Invasive lobular carcinoma (sparse breast tissue with necrosis)	T3N0M0		IIB	malignant	
H8	64	19	F	Breast	Invasive lobular carcinoma	T2N1M0		IIB	malignant	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880